BCBS Says Generic Xyrem Delay Was Antitrust Scheme

By Adam Lidgett (July 14, 2020, 8:51 PM EDT) -- Blue Cross Blue Shield Association has accused Jazz Pharmaceuticals in California federal court of paying off generic-drug makers to delay their rival versions of the pharmaceutical giant's brand name narcolepsy drug Xyrem, arguing the alleged scheme caused buyers to overpay for the drug....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!